iCAD (ICAD) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	ICAD INC
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		22,853,545

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,256	$ 15,313
Trade accounts receivable, net of allowance for doubtful accounts of $255 in 2020 and $136 in 2019	7,090	9,819
Inventory, net	2,462	2,611
Prepaid expenses and other current assets	1,497	1,453
Total current assets	25,305	29,196
Property and equipment, net of accumulated depreciation of $6,580 in 2020 and $6,510 in 2019	636	551
Operating lease assets	2,322	2,406
Other assets	93	50
Intangible assets, net of accumulated amortization of $8,263 in 2020 and $8,186 in 2019	1,107	1,183
Goodwill	8,362	8,362
Total assets	37,825	41,748
Current liabilities:
Accounts payable	1,674	1,990
Accrued and other expenses	6,100	6,590
Notes payable - current portion		4,250
Lease payable - current portion	809	758
Deferred revenue	5,259	5,248
Total current liabilities	13,842	18,836
Lease payable, long-term portion	1,707	1,837
Notes payable, long-term portion	6,957	2,003
Convertible debentures payable to non-related parties, at fair value		12,409
Convertible debentures payable to related parties, at fair value		1,233
Deferred revenue, long-term portion	232	356
Deferred tax	4	3
Total liabilities	22,742	36,677
Commitments and Contingencies (Note 7)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 30,000,000 shares; issued 21,425,916 in 2020 and 19,546,151 in 2019 outstanding 21,240,085 in 2020 and 19,360,320 in 2019.	215	195
Additional paid-in capital	252,419	230,615
Accumulated deficit	(236,136)	(224,324)
Treasury stock at cost, 185,831 shares in 2020 and 2019	(1,415)	(1,415)
Total stockholders' equity	15,083	5,071
Total liabilities and stockholders' equity	$ 37,825	$ 41,748

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 255	$ 136
Property and equipment, accumulated depreciation and amortization	6,580	6,510
Intangible assets, accumulated amortization	$ 8,263	$ 8,186
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	21,425,916	19,546,151
Common stock, shares outstanding	21,240,085	19,360,320
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 6,551	$ 6,773
Cost of revenue:
Amortization and depreciation	97	94
Total cost of revenue	2,041	1,491
Gross profit	4,510	5,282
Operating expenses:
Engineering and product development	2,211	2,127
Marketing and sales	3,608	2,573
General and administrative	2,532	1,546
Amortization and depreciation	52	70
Total operating expenses	8,403	6,316
Loss from operations	(3,893)	(1,034)
Interest expense	(130)	(209)
Other income	42	59
Loss on extinguishment of debt	(341)
Loss on fair value of convertible debentures	(7,464)	(2,525)
Other expense, net	(7,893)	(2,675)
Loss before income tax expense	(11,786)	(3,709)
Tax expense	(26)	(8)
Net loss and comprehensive loss	$ (11,812)	$ (3,717)
Net loss per share:
Basic	$ (0.59)	$ (0.22)
Diluted	$ (0.59)	$ (0.22)
Weighted average number of shares used in computing loss per share:
Basic	20,175	17,200
Diluted	20,175	17,200
Product [Member]
Revenue:
Total revenue	$ 3,795	$ 3,822
Cost of revenue:
Total cost of revenue	1,017	680
Service [Member]
Revenue:
Total revenue	2,756	2,951
Cost of revenue:
Total cost of revenue	$ 927	$ 717

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flow from operating activities:
Net loss	$ (11,812)	$ (3,717)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	79	95
Depreciation	70	69
Bad debt provision	119
Stock-based compensation expense	464	212
Amortization of debt discount and debt costs	40	39
Loss on extinguishment of debt	341
Deferred tax expense	1
Change in fair value of convertible debentures	7,464	2,525
Changes in operating assets and liabilities:
Accounts receivable	2,610	(984)
Inventory	149	(403)
Prepaid and other current assets	(72)	(347)
Accounts payable	(317)	330
Accrued expenses	(439)	414
Deferred revenue	(113)	(46)
Total adjustments	10,396	1,904
Net cash used for operating activities	(1,416)	(1,813)
Cash flow from investing activities:
Additions to patents, technology and other	(1)	(1)
Additions to property and equipment	(155)	(28)
Net cash used for investing activities	(156)	(29)
Cash flow from financing activities:
Stock option exercises	196	1,175
Principal payments of capital lease obligations		(3)
Principal repayment of debt financing	(4,638)	(200)
Repayment of line of credit	(2,000)
Proceeds from debt financing	7,000
Debt issuance costs	(43)
Net cash provided by financing activities	515	972
Decrease in cash and equivalents	(1,057)	(870)
Cash and equivalents, beginning of period	15,313	12,185
Cash and equivalents, end of period	14,256	11,315
Supplemental disclosure of cash flow information:
Interest paid	122	82
Taxes paid	26	8
Issuance of stock upon conversion of debentures	21,164
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 69	$ 907

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2018	$ 6,896	$ 171	$ 218,914	$ (210,774)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2018		17,066,510
Issuance of common stock relative to vesting of restricted stock	0	$ 1	(1)
Issuance of common stock relative to vesting of restricted stock, shares		66,334
Issuance of common stock pursuant to stock option plans	1,175	$ 3	1,172
Issuance of common stock pursuant to stock option plans, shares		367,421
Stock-based compensation	212		212
Net loss	(3,717)			(3,717)
Ending Balance at Mar. 31, 2019	4,566	$ 175	220,297	(214,491)	(1,415)
Ending Balance, shares at Mar. 31, 2019		17,500,265
Beginning Balance at Dec. 31, 2019	5,071	$ 196	230,616	(224,325)	(1,415)
Beginning Balance, shares at Dec. 31, 2019		19,546,151
Issuance of common stock relative to vesting of restricted stock
Issuance of common stock relative to vesting of restricted stock, shares		23,500
Issuance of common stock pursuant to stock option plans	196	$ 1	195
Issuance of common stock pursuant to stock option plans, shares		36,799
Issuance of stock for Debentures	21,164	$ 18	21,146
Issuance of stock for Debentures,Shares		1,819,466
Stock-based compensation	464		464
Net loss	(11,812)			(11,812)
Ending Balance at Mar. 31, 2020	$ 15,083	$ 215	$ 252,421	$ (236,137)	$ (1,415)
Ending Balance, shares at Mar. 31, 2020		21,425,916

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 - Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at March 31, 2020, the results of operations of the Company for the three- month period ended March 31, 2020 and 2019, and cash flows of the Company for the three-month period ended March 31, 2020 and 2019. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Segments The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products. Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19, COVID-19. COVID-19 COVID-19 The Company believes even if that event of default were to occur, the Company’s current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand, which now includes an additional estimated $12.2 million the Company received following the sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering which closed on April 27, 2020. Our results for the quarter ending March 31, 2020 reflect a negative impact from, among other things, the COVID-19 pandemic as shipping, logistics, acceptance and installation and training have been delayed and ordering patterns disrupted. Although we do not provide guidance to investors relating to our future results of operations, we expect that our results for the quarter ending June 30, 2020, and possibly future quarters, will reflect a negative impact from the COVID-19 pandemic for similar reasons. Depending upon the duration and severity of the pandemic, the continuing effect on our results over the long term is uncertain. The Company’s exposure to trade accounts receivable losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Recently Adopted Accounting Pronouncements There are no Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customer s Disaggregation of Revenue The following tables presents our revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to our reportable segments (in thousands). Three months ended March 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,100 $ 1,346 $ 4,446 Service contracts 1,347 347 1,694 Supply and source usage agreements — 371 371 Professional services — 11 11 Other 29 — 29 $ 4,476 $ 2,075 $ 6,551 Timing of Revenue Recognition Goods transferred at a point in time $ 3,129 $ 1,383 $ 4,512 Services transferred over time 1,347 692 2,039 $ 4,476 $ 2,075 $ 6,551 Sales Channels Direct sales force $ 2,172 $ 1,469 $ 3,641 OEM partners 2,304 — 2,304 Channel partners — 606 606 $ 4,476 $ 2,075 $ 6,551 Three months ended March 31, 2019 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,790 $ 1,519 $ 4,309 Service contracts 1,322 516 1,838 Supply and source usage agreements — 537 537 Professional services — 33 33 Other 56 — 56 $ 4,168 $ 2,605 $ 6,773 Timing of Revenue Recognition Goods transferred at a point in time $ 2,790 $ 1,632 $ 4,422 Services transferred over time 1,378 973 2,351 $ 4,168 $ 2,605 $ 6,773 Sales Channels Direct sales force $ 2,057 $ 1,812 $ 3,869 OEM partners 2,111 — 2,111 Channel partners — 793 793 $ 4,168 $ 2,605 $ 6,773 Products. Service Contracts. non-lease Supply and Source Usage Agreements. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, and contract assets are a component of prepaid and other current assets. The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands). Contract balances Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 7,090 Contract assets, which are included in “Prepaid and other current assets” 14 Contract liabilities, which are included in “Deferred revenue” 5,491 Timing of revenue recognition may differ from timing of invoicing to customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company’s accounts receivable from contracts with customers, net of allowance for doubtful accounts, was $7.1 million and $9.8 million as of March 31, 2020 and December 31, 2019, respectively. The Company will record a contract asset for unbilled revenue when the Company’s performance is in excess of amounts billed or billable. The Company has classified the contract asset balance as a component of prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019. The contract asset balance was $14,000 as of March 31, 2020 and December 31, 2019. Deferred revenue from contracts with customers is primarily composed of fees related to long-term service arrangements, which are generally billed in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which we have been paid in advance and earn the revenue when we transfer control of the product or service. Deferred revenue from contracts with customers is included in deferred revenue in the consolidated balance sheets. The balance of deferred revenue at March 31, 2020 and December 31, 2019 is as follows (in thousands): Contract liabilities March 31, 2020 December 31, 2019 Short term $ 5,259 $ 5,248 Long term 232 356 Total $ 5,491 $ 5,604 Changes in deferred revenue from contracts with customers were as follows (in thousands): Three Months Ended March 31, 2020 Balance at beginning of period $ 5,604 Deferral of revenue 2,226 Recognition of deferred revenue (2,339 ) Balance at end of period $ 5,491 We expect to recognize approximately $4.8 million of the deferred amount in 2020, $0.5 million in 2021, and $0.2 million thereafter.

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 2 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended 2020 2019 Net loss $ (11,812 ) $ (3,717 ) Shares used in the calculation of basic and diluted net loss per share 20,175 17,200 Diluted shares used in the calculation of net loss per share 20,175 17,200 Net loss per share - basic and diluted $ (0.59 ) $ (0.22 ) The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: Period Ended March 31, 2020 2019 Stock options 1,747,363 1,548,818 Restricted stock 74,492 270,064 Convertible Debentures — 1,742,500 Stock options and restricted stock 1,821,855 3,561,382

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Note 3 – Inventory Inventory is valued at the lower of cost or net realizable value, with cost determined by the first-in, first-out and as of March 31, as of December 31, Raw materials $ 1,502 $ 1,572 Work in process 97 39 Finished Goods 1,147 1,469 Inventory Gross 2,746 3,080 Inventory Reserve (284 ) (469 ) Inventory Net $ 2,462 $ 2,611

Financing Arrangements

Financing Arrangements	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Financing Arrangements	Note 4 – Financing Arrangements (a) Loan and Security Agreement – Silicon Valley Bank On August 7, 2017, the Company entered into a Loan and Security Agreement, which has since been modified, most recently by the Fifth Loan Modification Agreement dated as of November 1, 2019 ( as amended , the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”) that provided an initial term loan facility of $6.0 million and a $4.0 million revolving line of credit. On March 30, 2020, the Company elected to repay all outstanding obligations (including accrued interest) and retire the SVB Loan Agreement. The Company accounted for this repayment and retirement as an extinguishment of the SVB through , The loss on extinguishment was composed of approximately $185,000 for the unaccrued final payment , $114,000 termination fee, and and (b) Loan and Security Agreement – Western Alliance Bank On March 30 , 2020 the Company The Loan Agreement includes certain financial covenants tied to minimum revenue and maximum net loss. The Company was compliant with such covenants as of March 31, 2020. Subsequent to March 31, 2020 the Company, in accordance with the Loan Agreement, triggered the equity event that relieved the covenant related to maximum net loss, leaving only the minimum revenue requirement. Although the Company is no longer subject to the loan covenant tied to net loss, with the COVID-19 pandemic affecting the world economy, the Company cannot assure that it will be able to continue to satisfy the minimum revenue covenant. If at any point the Company is not in compliance with the covenant and is unable to obtain an amendment or waiver, such noncompliance may result in an event of default under the Loan Agreement, which could permit acceleration of the outstanding indebtedness and require the Company to repay such indebtedness before the scheduled due date. The Company was required, historically, to seek modifications from its prior lender to avoid non-compliance with its earlier covenants. Interest in arrears on the Term Loan will begin to be repaid on April 1, 2020 and continues the first of each successive month thereafter until the principal repayment starts. Commencing on the principal repayment date on of September 1, 2021 (or March 1, 2022 if the C a specified revenue target t . The interest rate is set at 1% above the Prime Rate. Prime Rate is defined in the Loan Agreement as the greater of four and a quarter percent (4.25%) or the Prime Rate published in the Money Rates section of the Western Edition of the Wall Street Journal . The Company has the . The Company prepayment is subject to payment of (1) all outstanding principal of the Term Loan plus accrued and unpaid interest thereon through the prepayment date, (2) the final payment ($122,500 or 1.75% of the original loan amount), (3) the prepayment fee (3% of principal balance if prepaid prior to first March 30, 2021, 2% if principal of prepaid after March 30, 2021 but before March 31, 2022, or 1% of principal if prepaid after March 30, 2022) plus (4) all other obligations that are due and payable, including Bank’s expenses and interest at the default rate with respect to any past due amounts. The Company did not draw against its revolving line of credit as of March 31, 2020. The interest rate on such borrowings, if the Company were to take an advance, is three quarters percent (0.75%) above the Prime Rate as defined above. Obligations to the Bank under the Loan Agreement are secured by a Company’s assets , except for certain permitted liens that have priority to the Bank’s security interest by operation of law. In connection with the Loan Agreement, the Company incurred approximately $43,000 of closing costs as of March 31, 2020. The closing costs have been deduced from the carrying value of the debt and will be amortized through March 30, 2022, the maturity date of the Term Loan. The maturity of the revolving loan is March 30, 2022. (c) Convertible Debentures On December 20, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited investors, including, but not limited to, all directors and executive officers of the Company at the time (the “Investors”), pursuant to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”) with an aggregate principal amount of approximately $7.0 million in a private placement. On February 21, 2020 (the “Conversion Date”), the conditions permitting a forced conversion were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures. On June 21, 2019 , At any time prior to the maturity date, the Convertible Debentures were convertible into shares of the Company’s common stock at a conversion price of $4.00 per share, at an was - were The Convertible Debentures also included certain liquidated damages provisions, whereby the Company would have been required to compensate the Investors for certain contingent events, such as the failure to timely deliver conversion shares of common stock, failure to timely pay any accrued interest when due and failure to timely issue certain public reports . Certain Investors in the Convertible Debentures included directors and employees of the Company. These related parties comprised approximately 9.6% of the principal value of the Convertible Debentures, or $670,000. The Convertible Debentures issued to the related parties had substantially the same rights and provisions as the unrelated third party investors, with the exception of certain terms where the related parties received less favorable terms than the unrelated third parties (such as with determination of the make - On the Conversion Date, the required conditions were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures. As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make - - - Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures The Company had previously elected to make a one-time, irrevocable As of the December 31, 2019 valuation and the prior measurement dates, the Company utilized a Monte Carlo simulation model to estimate the fair value of the Convertible Debentures. The simulation model was designed to capture the potential settlement features of the Convertible Debentures, in conjunction with simulated changes in the Company’s stock price and the probability of certain events occurring. The simulation utilized 100,000 trials or simulations to determine the estimated fair value. The simulation utilized the assumptions that if the Company was able to exercise its Forced Conversion right (if the requirements to do so are met), that it would do so in 100% of such scenarios. Additionally, if an event of default occurred during the simulated trial (based on the Company’s probability of default), the Investors would opt to redeem the Convertible Debentures in 100% of such scenarios. If neither event occurs during a simulated trial, the simulation assumed that the Investor would hold the Convertible Debentures until the maturity date. The value of the cash flows associated with each potential settlement were discounted to present value in each trial based on either the risk-free rate (for an equity settlement) or the effective discount rate (for a redemption or cash settlement). The Company also recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% of scenarios when the requirements were met, the final valuation was based on the actual results of the forced conversion. As such, the Company based the final fair value adjustment to the Convertible Debentures just prior to conversion on the number of shares of common stock that were issued to the Investors upon conversion and the fair value of the Company’s common stock as of the Conversion Date. The Company notes that the key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2019 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 Probabilty of default event 0.45 % N/A 1 Utilization of Forced Conversion (if available) 100.00 % 100.00 % 1 Exercise of Default Redemption (if available) 100.00 % N/A 1 Effective discount rate 18.52 % N/A 1 Represents a Level 3 unobservable input, as defined in Note 8—Fair Value Measurements, below. The Company’s stock price was was The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures, or remaining term under the expectation of the Company’s election of its forced conversion right. The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of public companies. The risk - The probability of the occurrence of a default event was based on Bloomberg’s 1 - The utilization of the forced conversion right and the default redemption right was The effective discount rate utilized at the December 31, 2019 valuation date was based on yields on CCC-rated The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December , 2019 February , 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970 The Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for period through the conversion date which are described in the additional fair value disclosures related to the Convertible Debentures in Note 8. Upon the consummation of the Forced Conversion, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million , which was reclassified to stockholders’ equity. The Convertible Debenture balance as of March 31, 2020 was $0. (d) Principal and Interest Payments Related to Financing Arrangements Future principal , , and final payment related to the Loan Agreement are as follows (in thousands): Fiscal Year Amount Due 2020 $ 281 2021 $ 1,238 2022 $ 2,875 2023 $ 2,735 2024 $ 1,004 Total $ 8,133 The following amounts are included in interest expense in our consolidated statement of operations for the three s 9 Three Months Ended March 31, 2020 2019 Cash interest expense $ 43 $ 82 Interest on convertible debentures 49 87 Accrual of notes payable final payment 31 32 Amortization of debt costs 7 7 Interest expense capital lease — 1 Total interest expense $ 130 $ 209

Lease Commitments

Lease Commitments	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 5 – Lease Commitments On January 1, 2019, the Company adopted ASC 842 and has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented. Under ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (i.e., an identified asset) for a period of time in exchange for consideration. Leases are classified as either operating or financing. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. The Company used its incremental borrowing rate to determine the present value of the lease payments. The Company determined the incremental borrowing rates for its leases by applying its applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement re-measurement right-of-use 360-10 Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Required Disclosures under ASC 842 The Company has leases for office space and office equipment. The leases have remaining lease terms ranging from less than one year to three years and six months as of March 31, 2020. The components of lease expense for the period are as follows (in thousands): Lease Cost Classification Three Months Ended March 31, 2020 Operating lease cost Operating expenses $ 224 Finance lease costs Amortization of leased assets Amortization and depreciation 4 Interest on lease liabilities Interest expense 1 Total $ 229 Other information related to leases was as follows (in thousands) Three Months Ended March 31, 2020 Cash paid for operating cash flows from operating leases $ 216 Cash paid for operating cash flows from finance leases 1 Cash paid for financing cash flows from finance leases 4 As of March 31, 2020 Weighted-average remaining lease term of operating leases (in years) 2.89 Weighted-average remaining lease term of finance leases (in years) 1.00 Weighted-average discount rate for operating leases 5.6 % Weighted-average discount rate for finance leases 11.0 % Maturity of the Company’s lease liabilities as of March 31, 2020 was as follows (in thousands): Three Months Ended March 31: Operating Leases Finance Leases Total 2020 692 9 701 2021 920 — 920 2022 899 — 899 2023 211 — 211 2024 5 — 5 Total lease payments 2,727 9 2,736 Less: imputed interest (219 ) (1 ) (220 ) Total lease liabilities 2,508 8 2,516 Less: current portion of lease liabilities (801 ) (8 ) (809 ) Long-term lease liabilities $ 1,707 $ — $ 1,707

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 6 - Stock-Based Compensation The Company granted options to purchase 48,285 and 196,737 shares of the Company’s stock during the three s Three Months Ended March 31, 2020 2019 Average risk-free interest rate 1.24% 2.38% Expected dividend yield None None Expected life 3.5 years 3.5 years Expected volatility 50.2% to 64.0% 53.1% to 54.2% Weighted average exercise price $8.26 $4.35 Weighted average fair value $3.19 $1.78 Remaining expense $1,632 $1,579 Weighted average term 1.0 1.0 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (in thousands): Three Months Ended March 31, 2020 2019 Cost of revenue $ 1 $ 1 Engineering and product development 54 87 Marketing and sales 58 59 General and administrative 351 65 $ 464 $ 212 As of March 31, 2020, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 1,632 Weighted average term 1.0 The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. During the three-month period ended March 31, 2020, the Company did not grant any restricted stock with time-based vesting while granting 14,000 shares in the three-month period ended March 31, 2019 . The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Three Months March 31, Aggregate intrinsic value 2020 2019 Stock options $ 4,749 $ 2,273 Restricted stock 547 1,396 The Company issued 36,799 shares of common stock upon the exercise of outstanding stock options in the three-month period ended March 31, 2020. The Company received cash proceeds of approximately $0.2 million in the three-month period ended March 31, 2020. The intrinsic value of restricted shares that vested in the three s Employee Stock Purchase Plan In December 2019, the 2019 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors and approved by stockholders, effective January 1, 2020. The ESPP provides for the issuance of up to Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to participate in the ESPP. Any eligible employee can enroll in the ESPP No shares had been issued under the ESPP as of March 31, 2020 and the company recorded approximately $34,000 of stock-based compensation expense pursuant to ESPP. The first accumulation period under the ESPP commenced on January 1, 2020 and was completed on March 31, 2020, and the related shares purchased by the participants were issued in April 2020. As of March 31, 2020, The Company recorded a liability of $151,000 related to employee withholdings, which was included as a component of accrued expenses and other current liabilities.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Foreign Tax Claim In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment the re-assessment excluding interest and penalties. The CRA has the right to pursue the matter until July 2020. The Company believes that it is not liable for the re-assessment Other Commitments The Company is obligated to pay approximately $5.9 million for firm purchase obligations to suppliers for future product and service deliverables. Litigation In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. In accordance with the agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 for a net of approximately $2.9 million. On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (“the Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No. 1:18-cv-08083-GBD, The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. The Company may be a party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 - Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable and convertible debentures. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments (except the Convertible Debentures, which were measured at fair value in accordance with the fair value option election) approximated fair value as of February 21, 2020 and December 31, 2019. The Company’s assets and liabilities that are measured at fair value on a recurring basis include the Company’s money market accounts and convertible debentures. The money market funds are included in cash and cash equivalents in the accompanying balance sheet and are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The Convertible Debentures were recorded as a separate component of the Company’s consolidated balance sheet and are considered a Level 3 measurement due to the utilization of significant unobservable inputs in their valuation. See Note 4(b) for a discussion of these fair value measurements. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements (000’s) as of December 31, 2019 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,313 $ — $ — $ 15,313 Total Assets $ 15,313 $ — $ — $ 15,313 Liabilities Convertible debentures $ — $ — $ 13,642 $ 13,642 Total Liabilities $ — $ — $ 13,642 $ 13,642 Fair Value Measurements (000’s) as of March 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 14,256 $ — $ — $ 14,256 Total Assets $ 14,256 $ — $ — $ 14,256 Liabilities Convertible debentures $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ — The following sets forth a reconciliation of the changes in the fair value of the Convertible Debentures that were Convertible Debenture Balance, December 31, 2019 $ 13,642 Fair value adjustments 7,522 Conversion (21,164 ) Balance, March 31, 2020 $ —

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 - The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted by the United States on March 27, 2020. Although the Company is continuing to analyze the impact of on its business, the CARES Act did not have a material impact on our provision for income taxes for the three months ended March 31, 2020. The Company recorded an income tax provision of $26,000 and $8,000 for the three-months ended March 31, 2020 and March 31, 2019, respectively. The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $4,000 related to tax amortizable goodwill. No other adjustments were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at March 31, 2020. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 10 - The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than the carrying value of the reporting unit. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company considered the goodwill impairment factors due to the uncertainty around the potential impact of the COVID-19 pandemic on the Company’s continuing operations and on the global economy as a whole. Under this consideration the Company performed scenario testing of the projections to the most recent impairment analysis performed as of October 1, 2019. The Company concluded that it did not have a triggering event or impairment indicators in the quarter ended March 31, 2020. The Company would record an impairment charge when such assessment indicates that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. The Company determines the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. T ha s , Detection and Therapy, A rollforward of goodwill activity by reportable segment is as follows (in thousands): Consolidated Detection Therapy Total Accumulated Goodwill 47,937 $ — $ — 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Prior to December 31, 2018 — 8,362 — 8,362 Balance at December 31, 2018 $ — $ 8,362 $ — $ 8,362 Balance at December 31, 2019 $ — $ 8,362 $ — $ 8,362 Balance at March 31, 2020 $ — $ 8,362 $ — $ 8,362

Long-lived assets

Long-lived assets	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 11 – Long-lived assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. There is no set interval or frequency for recoverability evaluation rather when to determine when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances .” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). The Company determined there were no If the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the fair value of the asset (or asset group). The Company determined the “Asset Group” of the Company to be the assets of the Cancer Therapy segment and the Cancer Detection segment, which the Company considers to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities. A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	Note 12 – Segment Reporting Operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM is the Chief Executive Officer. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Detection and Therapy. The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy products, “Axxent,” and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track assets by operating segment and our CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended 2020 2019 Segment revenues: Detection $ 4,476 $ 4,168 Therapy 2,075 2,605 Total Revenue $ 6,551 $ 6,773 Segment gross profit: Detection $ 3,467 $ 3,467 Therapy 1,043 1,815 Segment gross profit $ 4,510 $ 5,282 Segment operating income (loss): Detection $ (346 ) $ 302 Therapy (1,006 ) 221 Segment operating income (loss) $ (1,352 ) $ 523 General, administrative, depreciation and amortization expense $ (2,541 ) $ (1,557 ) Interest expense (130 ) (209 ) Other income 42 59 Loss on extinguishment of debt (341 ) — Fair value of convertible debentures (7,464 ) (2,525 ) Loss before income tax $ (11,786 ) $ (3,709 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Text Block [Abstract]
Recent Accounting Pronouncements	Note 13 - Recently Adopted Accounting Standards On January 1, 2020, the Company adopted ASU 2018-13, 2018-13”). 2018-13 2018-13 2018-13 Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, “Financial (“ASU 2016-13”), which ASU 2016-13 replaces 2016-13 2016-13 2016-13 In December 2019, the FASB issued ASU 2019-12, 2019-12”). 2019-12 2019-12 2019-12 In March 2020, the FASB issued ASU 2020-04, 2020-04”). ASU 2020-04 2020-04 2020-04

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On April 2 7 , issued to several institutional at a price of $8.00 per share in were , and the Company received net proceeds of approximately $12.2 million . The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct of post-market studies for the Company’s Xoft intra-operative radiation therapy (IORT) for glioblastoma and other brain cancers .

Stock-Based Compensation (Polic

Stock-Based Compensation (Policies)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at March 31, 2020, the results of operations of the Company for the three- month period ended March 31, 2020 and 2019, and cash flows of the Company for the three-month period ended March 31, 2020 and 2019. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K
Segments	Segments The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products. The Therapy segment consists of radiation therapy (“Axxent”) products.
Risk and Uncertainty	Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19, COVID-19. COVID-19 COVID-19 The Company believes even if that event of default were to occur, the Company’s current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand, which now includes an additional estimated $12.2 million the Company received following the sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering which closed on April 27, 2020. Our results for the quarter ending March 31, 2020 reflect a negative impact from, among other things, the COVID-19 pandemic as shipping, logistics, acceptance and installation and training have been delayed and ordering patterns disrupted. Although we do not provide guidance to investors relating to our future results of operations, we expect that our results for the quarter ending June 30, 2020, and possibly future quarters, will reflect a negative impact from the COVID-19 pandemic for similar reasons. Depending upon the duration and severity of the pandemic, the continuing effect on our results over the long term is uncertain. The Company’s exposure to trade accounts receivable losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements There are no
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customer s Disaggregation of Revenue The following tables presents our revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to our reportable segments (in thousands). Three months ended March 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,100 $ 1,346 $ 4,446 Service contracts 1,347 347 1,694 Supply and source usage agreements — 371 371 Professional services — 11 11 Other 29 — 29 $ 4,476 $ 2,075 $ 6,551 Timing of Revenue Recognition Goods transferred at a point in time $ 3,129 $ 1,383 $ 4,512 Services transferred over time 1,347 692 2,039 $ 4,476 $ 2,075 $ 6,551 Sales Channels Direct sales force $ 2,172 $ 1,469 $ 3,641 OEM partners 2,304 — 2,304 Channel partners — 606 606 $ 4,476 $ 2,075 $ 6,551 Three months ended March 31, 2019 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,790 $ 1,519 $ 4,309 Service contracts 1,322 516 1,838 Supply and source usage agreements — 537 537 Professional services — 33 33 Other 56 — 56 $ 4,168 $ 2,605 $ 6,773 Timing of Revenue Recognition Goods transferred at a point in time $ 2,790 $ 1,632 $ 4,422 Services transferred over time 1,378 973 2,351 $ 4,168 $ 2,605 $ 6,773 Sales Channels Direct sales force $ 2,057 $ 1,812 $ 3,869 OEM partners 2,111 — 2,111 Channel partners — 793 793 $ 4,168 $ 2,605 $ 6,773 Products. Service Contracts. non-lease Supply and Source Usage Agreements. Professional Services. Other. Contract Balances Contract liabilities are a component of deferred revenue, and contract assets are a component of prepaid and other current assets. The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands). Contract balances Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 7,090 Contract assets, which are included in “Prepaid and other current assets” 14 Contract liabilities, which are included in “Deferred revenue” 5,491 Timing of revenue recognition may differ from timing of invoicing to customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company’s accounts receivable from contracts with customers, net of allowance for doubtful accounts, was $7.1 million and $9.8 million as of March 31, 2020 and December 31, 2019, respectively. The Company will record a contract asset for unbilled revenue when the Company’s performance is in excess of amounts billed or billable. The Company has classified the contract asset balance as a component of prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019. The contract asset balance was $14,000 as of March 31, 2020 and December 31, 2019. Deferred revenue from contracts with customers is primarily composed of fees related to long-term service arrangements, which are generally billed in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which we have been paid in advance and earn the revenue when we transfer control of the product or service. Deferred revenue from contracts with customers is included in deferred revenue in the consolidated balance sheets. The balance of deferred revenue at March 31, 2020 and December 31, 2019 is as follows (in thousands): Contract liabilities March 31, 2020 December 31, 2019 Short term $ 5,259 $ 5,248 Long term 232 356 Total $ 5,491 $ 5,604 Changes in deferred revenue from contracts with customers were as follows (in thousands): Three Months Ended March 31, 2020 Balance at beginning of period $ 5,604 Deferral of revenue 2,226 Recognition of deferred revenue (2,339 ) Balance at end of period $ 5,491 We expect to recognize approximately $4.8 million of the deferred amount in 2020, $0.5 million in 2021, and $0.2 million thereafter.
Litigation	Litigation In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. In accordance with the agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 for a net of approximately $2.9 million. On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (“the Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No. 1:18-cv-08083-GBD, The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. The Company may be a party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.
Fair Value Measurements	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable and convertible debentures. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments (except the Convertible Debentures, which were measured at fair value in accordance with the fair value option election) approximated fair value as of February 21, 2020 and December 31, 2019. The Company’s assets and liabilities that are measured at fair value on a recurring basis include the Company’s money market accounts and convertible debentures. The money market funds are included in cash and cash equivalents in the accompanying balance sheet and are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The Convertible Debentures were recorded as a separate component of the Company’s consolidated balance sheet and are considered a Level 3 measurement due to the utilization of significant unobservable inputs in their valuation. See Note 4(b) for a discussion of these fair value measurements. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements (000’s) as of December 31, 2019 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,313 $ — $ — $ 15,313 Total Assets $ 15,313 $ — $ — $ 15,313 Liabilities Convertible debentures $ — $ — $ 13,642 $ 13,642 Total Liabilities $ — $ — $ 13,642 $ 13,642 Fair Value Measurements (000’s) as of March 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 14,256 $ — $ — $ 14,256 Total Assets $ 14,256 $ — $ — $ 14,256 Liabilities Convertible debentures $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ — The following sets forth a reconciliation of the changes in the fair value of the Convertible Debentures that were Convertible Debenture Balance, December 31, 2019 $ 13,642 Fair value adjustments 7,522 Conversion (21,164 ) Balance, March 31, 2020 $ —
Income Taxes	The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted by the United States on March 27, 2020. Although the Company is continuing to analyze the impact of on its business, the CARES Act did not have a material impact on our provision for income taxes for the three months ended March 31, 2020. The Company recorded an income tax provision of $26,000 and $8,000 for the three-months ended March 31, 2020 and March 31, 2019, respectively. The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $4,000 related to tax amortizable goodwill. No other adjustments were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at March 31, 2020. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.
Intangibles - Goodwill and Other	The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than the carrying value of the reporting unit. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company considered the goodwill impairment factors due to the uncertainty around the potential impact of the COVID-19 pandemic on the Company’s continuing operations and on the global economy as a whole. Under this consideration the Company performed scenario testing of the projections to the most recent impairment analysis performed as of October 1, 2019. The Company concluded that it did not have a triggering event or impairment indicators in the quarter ended March 31, 2020. The Company would record an impairment charge when such assessment indicates that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. The Company determines the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. T ha s , Detection and Therapy, A rollforward of goodwill activity by reportable segment is as follows (in thousands): Consolidated Detection Therapy Total Accumulated Goodwill 47,937 $ — $ — 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Prior to December 31, 2018 — 8,362 — 8,362 Balance at December 31, 2018 $ — $ 8,362 $ — $ 8,362 Balance at December 31, 2019 $ — $ 8,362 $ — $ 8,362 Balance at March 31, 2020 $ — $ 8,362 $ — $ 8,362
Long-lived assets	The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. There is no set interval or frequency for recoverability evaluation rather when to determine when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances .” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). The Company determined there were no If the carrying amount of an asset or asset group (in use or under development) is evaluated and found not to be fully recoverable (the carrying amount exceeds the estimated gross, undiscounted cash flows from use and disposition), then an impairment loss must be recognized. The impairment loss is measured as the excess of the carrying amount over the fair value of the asset (or asset group). The Company determined the “Asset Group” of the Company to be the assets of the Cancer Therapy segment and the Cancer Detection segment, which the Company considers to be the lowest level for which the identifiable cash flows were largely independent of the cash flows of other assets and liabilities. A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the asset group and the reporting unit. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges.
Segment Reporting	Operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents our revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to our reportable segments (in thousands). Three months ended March 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,100 $ 1,346 $ 4,446 Service contracts 1,347 347 1,694 Supply and source usage agreements — 371 371 Professional services — 11 11 Other 29 — 29 $ 4,476 $ 2,075 $ 6,551 Timing of Revenue Recognition Goods transferred at a point in time $ 3,129 $ 1,383 $ 4,512 Services transferred over time 1,347 692 2,039 $ 4,476 $ 2,075 $ 6,551 Sales Channels Direct sales force $ 2,172 $ 1,469 $ 3,641 OEM partners 2,304 — 2,304 Channel partners — 606 606 $ 4,476 $ 2,075 $ 6,551 Three months ended March 31, 2019 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,790 $ 1,519 $ 4,309 Service contracts 1,322 516 1,838 Supply and source usage agreements — 537 537 Professional services — 33 33 Other 56 — 56 $ 4,168 $ 2,605 $ 6,773 Timing of Revenue Recognition Goods transferred at a point in time $ 2,790 $ 1,632 $ 4,422 Services transferred over time 1,378 973 2,351 $ 4,168 $ 2,605 $ 6,773 Sales Channels Direct sales force $ 2,057 $ 1,812 $ 3,869 OEM partners 2,111 — 2,111 Channel partners — 793 793 $ 4,168 $ 2,605 $ 6,773
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands). Contract balances Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 7,090 Contract assets, which are included in “Prepaid and other current assets” 14 Contract liabilities, which are included in “Deferred revenue” 5,491
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows (in thousands): Three Months Ended March 31, 2020 Balance at beginning of period $ 5,604 Deferral of revenue 2,226 Recognition of deferred revenue (2,339 ) Balance at end of period $ 5,491
Accounting Standards Update 2016-02 [Member]
Summary of Changes in Deferred Revenue	The balance of deferred revenue at March 31, 2020 and December 31, 2019 is as follows (in thousands): Contract liabilities March 31, 2020 December 31, 2019 Short term $ 5,259 $ 5,248 Long term 232 356 Total $ 5,491 $ 5,604

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended 2020 2019 Net loss $ (11,812 ) $ (3,717 ) Shares used in the calculation of basic and diluted net loss per share 20,175 17,200 Diluted shares used in the calculation of net loss per share 20,175 17,200 Net loss per share - basic and diluted $ (0.59 ) $ (0.22 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock issuable upon the exercise of convertible securities, stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: Period Ended March 31, 2020 2019 Stock options 1,747,363 1,548,818 Restricted stock 74,492 270,064 Convertible Debentures — 1,742,500 Stock options and restricted stock 1,821,855 3,561,382

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Current Inventory	as of March 31, as of December 31, Raw materials $ 1,502 $ 1,572 Work in process 97 39 Finished Goods 1,147 1,469 Inventory Gross 2,746 3,080 Inventory Reserve (284 ) (469 ) Inventory Net $ 2,462 $ 2,611

Financing Arrangements (Tables)

Financing Arrangements (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures	The Company notes that the key inputs to the valuation models that were utilized to estimate the fair value of the Convertible Debentures included: Input December 31, 2019 February 21, 2019 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 0.45 % N/A 1 100.00 % 100.00 % 1 100.00 % N/A 1 18.52 % N/A 1 Represents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below.
Schedule of Fair Value and Principal Value of Convertible Debentures	The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures 12/31/2019 2/21/2019 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970
Summary of Future Principal and Interest Payments Related to Loan Agreement and Convertible Debentures	Future principal and interest payments related to the Loan Agreement are as follows (in thousands): Fiscal Year Amount Due 2020 $ 281 2021 $ 1,238 2022 $ 2,875 2023 $ 2,735 2024 $ 881 Total $ 8,010
Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in our consolidated statement of operations for the three-month ended March 31, 2020 and 2018 (in thousands): Three Months Ended March 31, 2020 2019 Cash interest expense $ 43 $ 82 Interest on convertible debentures 49 87 Accrual of notes payable final payment 31 32 Amortization of debt costs 7 7 Interest expense capital lease — 1 Total interest expense $ 130 $ 209

Lease Commitments (Tables)

Lease Commitments (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The components of lease expense for the period are as follows (in thousands): Lease Cost Classification Three Months Ended March 31, 2020 Operating lease cost Operating expenses $ 224 Finance lease costs Amortization of leased assets Amortization and depreciation 4 Interest on lease liabilities Interest expense 1 Total $ 229 Other information related to leases was as follows (in thousands) Three Months Ended March 31, 2020 Cash paid for operating cash flows from operating leases $ 216 Cash paid for operating cash flows from finance leases 1 Cash paid for financing cash flows from finance leases 4 As of March 31, 2020 Weighted-average remaining lease term of operating leases (in years) 2.89 Weighted-average remaining lease term of finance leases (in years) 1.00 Weighted-average discount rate for operating leases 5.6 % Weighted-average discount rate for finance leases 11.0 %
Summary of Detained Information of Lease Liabilities	Maturity of the Company’s lease liabilities as of March 31, 2020 was as follows (in thousands): Three Months Ended March 31: Operating Leases Finance Leases Total 2020 692 9 701 2021 920 — 920 2022 899 — 899 2023 211 — 211 2024 5 — 5 Total lease payments 2,727 9 2,736 Less: imputed interest (219 ) (1 ) (220 ) Total lease liabilities 2,508 8 2,516 Less: current portion of lease liabilities (801 ) (8 ) (809 ) Long-term lease liabilities $ 1,707 $ — $ 1,707

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Three Months Ended March 31, 2020 2019 Average risk-free interest rate 1.24% 2.38% Expected dividend yield None None Expected life 3.5 years 3.5 years Expected volatility 50.2% to 64.0% 53.1% to 54.2% Weighted average exercise price $8.26 $4.35 Weighted average fair value $3.19 $1.78 Remaining expense $1,632 $1,579 Weighted average term 1.0 1.0
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (in thousands): Three Months Ended March 31, 2020 2019 Cost of revenue $ 1 $ 1 Engineering and product development 54 87 Marketing and sales 58 59 General and administrative 351 65 $ 464 $ 212
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period	As of March 31, 2020, unrecognized compensation cost (in thousands) related to unvested options and unvested restricted stock and the weighted average term of such equity instruments is as follows: Remaining expense $ 1,632 Weighted average term 1.0
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Three Months March 31, Aggregate intrinsic value 2020 2019 Stock options $ 4,749 $ 2,273 Restricted stock 547 1,396

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands). Fair Value Measurements (000’s) as of December 31, 2019 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 15,313 $ — $ — $ 15,313 Total Assets $ 15,313 $ — $ — $ 15,313 Liabilities Convertible debentures $ — $ — $ 13,642 $ 13,642 Total Liabilities $ — $ — $ 13,642 $ 13,642 Fair Value Measurements (000’s) as of March 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 14,256 $ — $ — $ 14,256 Total Assets $ 14,256 $ — $ — $ 14,256 Liabilities Convertible debentures $ — $ — $ — $ — Total Liabilities $ — $ — $ — $ —
Schedule of Reconciliation of Changes In Fair Value of Convertible Debentures	The following sets forth a reconciliation of the changes in the fair value of the Convertible Debentures that were Convertible Debenture Balance, December 31, 2019 $ 13,642 Fair value adjustments 7,522 Conversion (21,164 ) Balance, March 31, 2020 $ —

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Roll Forward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows (in thousands): Consolidated Detection Therapy Total Accumulated Goodwill 47,937 $ — $ — 47,937 Accumulated impairment (26,828 ) — — (26,828 ) Fair value allocation (21,109 ) 7,663 13,446 — Acquisition of DermEbx and Radion — — 6,154 6,154 Acquisition measurement period adjustments — — 116 116 Acquisition of VuComp — 1,093 — 1,093 Sale of MRI assets — (394 ) (394 ) Impairment — — (19,716 ) (19,716 ) Prior to December 31, 2018 — 8,362 — 8,362 Balance at December 31, 2018 $ — $ 8,362 $ — $ 8,362 Balance at December 31, 2019 $ — $ 8,362 $ — $ 8,362 Balance at March 31, 2020 $ — $ 8,362 $ — $ 8,362

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to US GAAP loss before income tax is as follows (in thousands): Three Months Ended 2020 2019 Segment revenues: Detection $ 4,476 $ 4,168 Therapy 2,075 2,605 Total Revenue $ 6,551 $ 6,773 Segment gross profit: Detection $ 3,467 $ 3,467 Therapy 1,043 1,815 Segment gross profit $ 4,510 $ 5,282 Segment operating income (loss): Detection $ (346 ) $ 302 Therapy (1,006 ) 221 Segment operating income (loss) $ (1,352 ) $ 523 General, administrative, depreciation and amortization expense $ (2,541 ) $ (1,557 ) Interest expense (130 ) (209 ) Other income 42 59 Loss on extinguishment of debt (341 ) — Fair value of convertible debentures (7,464 ) (2,525 ) Loss before income tax $ (11,786 ) $ (3,709 )

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 27, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment | Segment		2
Contract assets		$ 14	$ 14
Unearned amount to recognize in 2020		4,800
Unearned amount to recognize in 2021		500
Unearned amount to recognize, thereafter		200
Subsequent Event [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Proceeds from sale of stock	$ 12,200
Sale of stock price per share | $ / shares	$ 8
Direct Offering [Member] | Subsequent Event [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Proceeds from sale of stock	$ 12,200
Number of shares sold | shares	1,562,500
Sale of stock price per share | $ / shares	$ 8
Revenue from Contract with Customer [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Allowance for doubtful accounts, receivable		$ 7,100	$ 9,800

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 6,551	$ 6,773
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,446	4,309
Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,694	1,838
Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	371	537
Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	11	33
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	29	56
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,512	4,422
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,039	2,351
Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,641	3,869
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,304	2,111
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	606	793
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,476	4,168
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,100	2,790
Detection [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,347	1,322
Detection [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	29	56
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,129	2,790
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,347	1,378
Detection [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,172	2,057
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,304	2,111
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,075	2,605
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,346	1,519
Therapy [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	347	516
Therapy [Member] | Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	371	537
Therapy [Member] | Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	11	33
Therapy [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	0	0
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,383	1,632
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	692	973
Therapy [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,469	1,812
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 606	$ 793

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in 'Trade accounts receivable'	$ 7,090
Contract assets, which are included in "Prepaid and other current assets"	14	$ 14
Contract liabilities, which are included in "Deferred revenue"	$ 5,491	$ 5,604

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 5,491	$ 5,604
Short-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	5,259	5,248
Long-term Contract with Customer [Member]
Deferred Revenue Arrangement [Line Items]
Contract liabilities	$ 232	$ 356

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 5,604
Deferral of revenue	2,226
Recognition of deferred revenue	(2,339)
Balance at end of period	$ 5,491

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (11,812)	$ (3,717)
Shares used in the calculation of basic and diluted net loss per share	20,175	17,200
Effect of dilutive securities:
Diluted shares used in the calculation of net loss per share	20,175	17,200
Net loss per share - basic and diluted	$ (0.59)	$ (0.22)

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,821,855	3,561,382
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,747,363	1,548,818
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	74,492	270,064
Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock		1,742,500

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory reserve	$ 284	$ 469

Inventory - Schedule of Current

Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,502	$ 1,572
Work in process	97	39
Finished Goods	1,147	1,469
Inventory Gross	2,746	3,080
Inventory Reserve	(284)	(469)
Inventory Net	$ 2,462	$ 2,611

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail)	Mar. 30, 2020USD ($)	Mar. 31, 2020USD ($)Trialcustomer$ / sharesshares	Dec. 31, 2019USD ($)	Feb. 21, 2019USD ($)	Aug. 07, 2017USD ($)
Debt Instrument [Line Items]
Debt insrument redemption description		The simulation utilized the assumptions that if the Company is able to exercise its Forced Conversion right (if the requirements to do so are met), that it will do so in 100% of such scenarios. Additionally, if an event of default occurs during the simulated trial (based on the Company’s probability of default), the Investors will opt to redeem the Convertible Debentures in 100% of such scenarios
Loss from fair value of the convertible debentures		$ 7,500,000
Loss on extinguishment of debt		(341,000)
Final payment of loan	$ 510,000
Rreclassified the fair value of convertible debentures			$ 13,642,000	$ 21,164,000
Outstanding debt		$ 0
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Accrued final payment loan	325,000
Termination fee	114,000
Other costs	10,000
Loss on extinguishment of debt	341,000
Final payment of loan	185,000
Unamortized closing costs	42,000
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Percentage of final payment		1.75%
Final Payment		$ 122,500
Description of prepayment pee		the prepayment fee (3% of principal balance if prepaid prior to first March 30, 2021, 2% if principal of prepaid after March 30, 2021 but before March 31, 2022, or 1% of principal if prepaid after March 30, 2022) plus
Line of credit, closing costs		$ 43,000
Interest Rate Description		1% above the Prime Rate
Western Alliance Bank [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		4.25%
Western Alliance Bank [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		1.00%
Convertible Debt [Member]
Debt Instrument [Line Items]
Percentage of final payment		5.00%
Aggregate principal amount			$ 7,000,000
Maturity date		Dec. 21, 2021
Debt conversion, conversion price per share | $ / shares		$ 4
Convertible debenture Number of instrumnts converted | customer		1,742,500
Shares issued up on conversion | shares		1,816,466
Convertible Debt [Member] | Make Whole Provision [Member]
Debt Instrument [Line Items]
Aggregate principal amount		$ 697,000
Convertible debenture Number of instrumnts converted | customer		76,966
Convertible Debt [Member] | Monte Carlo Simulation [Member]
Debt Instrument [Line Items]
Number of trials to detremine fair value | Trial		100,000
Convertible Debt [Member] | Directors And Employees [Member]
Debt Instrument [Line Items]
Aggregate principal amount		$ 670,000
Purchase pecentage of principal value of convertible debentures		9.60%
Term Loan A [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility					$ 6,000,000
Term Loan A [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility	7,000,000
Description of arrears repayment if revenue goal achieved		Interest in arrears on the Term Loan will begin to be repaid on April 1, 2020 and continues the first of each successive month thereafter until the principal repayment starts. Commencing on the principal repayment date on of September 1, 2021 (or March 1, 2022 if the company achieves the revenue goal set by the Bank of $17,000,000 for any trailing six month period prior to December 31, 2020) and continuing on the first day of each month thereafter, The Company shall make equal monthly payments of principal, together with applicable interest in arrears, to Bank, as calculated by Bank equal monthly installments of principal.
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Interest Rate Description		(0.75%) above the Prime Rate
Revolving Credit Facility [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Interest Rate During Period		0.75%
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility					$ 4,000,000
Revolving Credit Facility [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility	$ 5,000,000

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures (Detail) - Convertible Debt [Member]		Dec. 31, 2019yr	Feb. 21, 2019yr
Company's Stock Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		7.77	11.64
Conversion Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		4	4
Remaining Term (Years) [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		1.97	0
Equity Volatility [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		49
Risk Free Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		1.57
Probability of Default Event [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	0.45
Utilization of Forced Conversion [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	100	100
Exercise of Default Redemption [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	100
Effective Discount Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	18.52
[1]	Represents a Level 3 unobservable input, as defined in Note 8 - Fair Value Measurements, below.

Financing Arrangements - Sche_2

Financing Arrangements - Schedule of Fair Value and Principal Value of Convertible Debentures (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Feb. 21, 2019
Debt Disclosure [Abstract]
Fair value, in accordance with fair value option	$ 13,642	$ 21,164
Principal value outstanding	$ 6,970	$ 6,970

Finance Arrangements - Summary

Finance Arrangements - Summary of Future Principal and Interest Payments Related to Loan Agreement and Convertible Debentures (Detail) - Term Loan A [Member] $ in Thousands	Mar. 31, 2020USD ($)
Shares Issued And Outstanding [Line Items]
2020	$ 281
2021	1,238
2022	2,875
2023	2,735
2024	1,004
Total	$ 8,133

Finance Arrangements - Interest

Finance Arrangements - Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Interest Expense [Line Items]
Cash interest expense	$ 43	$ 82
Interest on convertible debentures	49	87
Accrual of notes payable final payment	31	32
Amortization of debt costs	7	7
Interest expense capital lease		1
Total interest expense	$ 130	$ 209

Lease Commitments - Additional

Lease Commitments - Additional Information (Detail)	Mar. 31, 2020
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	3 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year

Lease Commitments - Schedule of

Lease Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost - Right of Use	$ 224
Finance lease costs
Amortization of leased assets	4
Interest on lease liabilities Interest expense	1
Total	229
Cash paid for operating cash flows from operating leases	216
Cash paid for operating cash flows from finance leases	1
Cash paid for financing cash flows from finance leases	$ 4
Weighted-average remaining lease term of operating leases (in years)	2 years 10 months 20 days
Weighted-average remaining lease term of finance leases (in years)	1 year
Weighted-average discount rate for operating leases	5.60%
Weighted-average discount rate for finance leases	11.00%

Lease Commitments - Summary of

Lease Commitments - Summary of Detained Information of Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 692
2021	920
2022	899
2023	211
2024	5
Total	2,727
Less: imputed interest	(219)
Total lease liabilities	2,508
Less: current portion of lease liabilities	(801)
Total lease liabilities	1,707
2020	9
Total lease payments	9
Less: imputed interest	(1)
Total lease liabilities	8
Less: current portion of lease liabilities	(8)
2020	701
2021	920
2022	899
2023	211
2024	5
Total lease payments	2,736
Less: imputed interest	(220)
Total lease liabilities	2,516
Less: current portion of lease liabilities	(809)	$ (758)
Long-term lease liabilities	$ 1,707

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 464	$ 212
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	1	1
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	54	87
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	58	59
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 351	$ 65

Stockholders' Equity - Options

Stockholders' Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 8.26	$ 4.35
Weighted average fair value	$ 3.19	$ 1.78
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	64.00%	54.20%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	50.20%	53.10%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			14,000
Accrued salary and related expenses		$ 151,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of restricted shares that vested		$ 0.4
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, Issued		36,799
Net proceeds from Issue of common stock		$ 0.2
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued, Employee Stock Purchase Plans	950,000
Percentage of voting power	5.00%
Description of employee stock purchase plan	Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.
Stock-based compensation expense		$ 34,000
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted		48,285	196,737

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	1.24%	2.38%
Expected dividend yield	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 8.26	$ 4.35
Weighted average fair value	$ 3.19	$ 1.78
Remaining expense	$ 1,632		$ 1,579
Weighted average term	1 year	1 year
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	50.20%	53.10%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	64.00%	54.20%

Stock-Based Compensation - Unre

Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]
Remaining expense	$ 1,632
Weighted average term	1 year

Stock-Based Compensation - Aggr

Stock-Based Compensation - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options	$ 4,749	$ 2,273
Restricted stock	$ 547	$ 1,396

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended
	Feb. 28, 2010	Jul. 31, 2007	Mar. 31, 2020	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables			$ 5,900,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Schedule Of Leases [Line Items]
Sale and transfer of intangible assets					$ 3,200,000
Holdback reserve related to sale and transfer of intangible assets				$ 350,000
Proceeds from sale and transfer of intangible assets				$ 2,900,000
CADx Medical Systems Inc [Member]
Schedule Of Leases [Line Items]
Tax re-assessment received		$ 6,800,000
Reduced tax re-assessment received	$ 703,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets
Total Assets	$ 14,256	$ 15,313
Liabilities
Total Liabilities		13,642
Convertible Debentures [Member]
Liabilities
Total Liabilities		13,642
Money Market Accounts [Member]
Assets
Total Assets	14,256	15,313
Level 1 [Member]
Assets
Total Assets	14,256	15,313
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 14,256	15,313
Level 3 [Member]
Liabilities
Total Liabilities		13,642
Level 3 [Member] | Convertible Debentures [Member]
Liabilities
Total Liabilities		$ 13,642

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Reconciliation of Changes In Fair Value of Convertible Debentures (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Feb. 21, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 13,642
Conversion		$ (13,642)	$ (21,164)
Convertible Debentures [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	13,642
Fair value adjustment	7,522
Conversion	$ (21,164)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0
Income tax provision	26,000	$ 8,000
Deferred tax liability related to amortized goodwill	$ 4,000

Goodwill - Roll Forward of Good

Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2020	Dec. 31, 2019
Accumulated Goodwill	$ 47,937
Accumulated impairment	(26,828)
Acquisition measurement period adjustments	116
Sale of MRI assets	(394)
Impairment	(19,716)
Goodwill, Ending Balance	8,362	$ 8,362	$ 8,362
DermEbx And Radion [Member]
Acquisition cost	6,154
VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Consolidated Reporting Unit [Member]
Accumulated Goodwill	47,937
Accumulated impairment	(26,828)
Fair value allocation	(21,109)
Detection [Member]
Fair value allocation	7,663
Sale of MRI assets	(394)
Goodwill, Ending Balance	8,362	$ 8,362	$ 8,362
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Acquisition cost	1,093
Therapy [Member]
Fair value allocation	13,446
Acquisition measurement period adjustments	116
Impairment	(19,716)
Therapy [Member] | DermEbx And Radion [Member]
Acquisition cost	$ 6,154

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment revenues:
Total Revenue	$ 6,551	$ 6,773
Segment gross profit:
Segment gross profit	4,510	5,282
Segment operating income (loss):
Segment operating income (loss)	(1,352)	523
General, administrative, depreciation and amortization expense	(2,541)	(1,557)
Interest expense	(130)	(209)
Other income	42	59
Fair value of convertible debentures	(7,464)	(2,525)
Loss on extinguishment of debt	(341)
Loss before income tax expense	(11,786)	(3,709)
Product [Member]
Segment revenues:
Total Revenue	3,795	3,822
Service [Member]
Segment revenues:
Total Revenue	2,756	2,951
Detection [Member]
Segment gross profit:
Segment gross profit	3,467	3,467
Segment operating income (loss):
Segment operating income (loss)	(346)	302
Detection [Member] | Product [Member]
Segment revenues:
Total Revenue	4,476	4,168
Therapy [Member]
Segment gross profit:
Segment gross profit	1,043	1,815
Segment operating income (loss):
Segment operating income (loss)	(1,006)	221
Therapy [Member] | Service [Member]
Segment revenues:
Total Revenue	$ 2,075	$ 2,605

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] $ / shares in Units, $ in Millions	Apr. 27, 2020USD ($)$ / sharesshares
Issue of common stock | shares	1,562,500
Sale of Stock, Price Per Share | $ / shares	$ 8
Gross proceeds from Issue of common stock	$ 12.5
Net proceeds from Issue of common stock	$ 12.2